The lancet oncology
-
The lancet oncology · May 2010
Randomized Controlled TrialPrognostic effect of chromosomal abnormalities in childhood B-cell precursor acute lymphoblastic leukaemia: results from the UK Medical Research Council ALL97/99 randomised trial.
Chromosomal abnormalities in childhood acute lymphoblastic leukaemia are well established disease markers and indicators of outcomes. However, the long-term prognosis and independent prognostic effect of some abnormalities has been questioned. Also, little is known about the association between cytogenetics and the characteristics of relapse (eg, time and site of relapse) that are known to predict outcome after relapse. ⋯ Leukaemia and Lymphoma Research (LLR).
-
The lancet oncology · May 2010
Randomized Controlled TrialEffect of zoledronic acid on disseminated tumour cells in women with locally advanced breast cancer: an open label, randomised, phase 2 trial.
Treatment with bisphosphonates decreases bone loss and can increase disease-free survival in patients with breast cancer. The aim of our study was to assess the effect of zoledronic acid on clearance of disseminated tumour cells (DTCs) from the bone marrow in women undergoing neoadjuvant chemotherapy for breast cancer. ⋯ Novartis Pharmaceuticals and Pfizer Inc.
-
The lancet oncology · May 2010
Risk of thromboembolic diseases in men with prostate cancer: results from the population-based PCBaSe Sweden.
Cancer is associated with an increased risk of thromboembolic diseases, but data on the association between prostate cancer and thromboembolic diseases are scarce. We investigated the risk of thromboembolic disease in men with prostate cancer who were receiving endocrine treatment, curative treatment, or surveillance. ⋯ Swedish Research Council, Stockholm Cancer Society, and Cancer Research UK.